Jounce Therapeutics (NASDAQ:JNCE) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.36) by 77.78 percent. This is a 90.24 percent increase over losses of $(0.82) per share from the same period last year.
Uber CEO Says Co To Monetize Non-Strategic Stakes In Other Companies, Including China’s DiDi, Over Time
-Reuters Citing UBS Conference
